Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.
Park
S
S
Vassilieff
D
D
Bardet
V
V
Viguié
F
F
Dreyfus
F
F
D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000209:etiology / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D017384:Sequence Deletion; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D013792:Thalidomide; D000077269:Lenalidomide